Overview
Cerevel Therapeutics was a clinical-stage neuroscience company developing selective receptor-targeted therapies for schizophrenia, Parkinson's disease, and epilepsy, best known for emraclidine, a muscarinic receptor agonist for schizophrenia. Cerevel was acquired by AbbVie in 2024 for approximately $8.7 billion.
More in Neuropharmaceuticals
Latest industry news
It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
2026-06-23 · Product
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
💊 Neuropharmaceuticals
Location
Cambridge, USA
Funding
Acquired · AbbVie 2024
Website
www.cerevel.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →